Interview with Calliditas "This is good news from our perspective"

Calliditas Therapeutics announced this month that the US FDA requires an additional 3 months to review the submission for Nefecon, so our analyst took a few minutes with CEO Renee Aguiar-Lucander, to go through where the company stands now. “The information in this video should not be seen as an investment advice.

Keep in mind that investments in securities always carry a risk. Historical returns are no guarantee of future returns. The money invested in securities can both increase and decrease in value and there is no guarantee that you will get back the amount invested.

It is important to continuously monitor your holdings and if necessary take actions to reduce the risk of loss." http://www.paretosec.com/download/compliance/disclaimer.pdf.